Oncotype DX Genomic Prostate Score

Interpreting GPS Results

Predict both clinical risk and tumor aggressiveness

Oncotype DX GPS is proven to be an independent predictor of:both clinical risk and tumor aggressiveness after radical prostatectomy for patients with biopsy Gleason scores of 3+3 and 3+41-3.

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report.

 

See sample reports

For patients with:

Getting your results

Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Genomic Health Laboratory. You can access the results through the online physician portal or receive the report by fax.

Start Report Guide
Start Report Guide
Start Report Guide
Start Report Guide
Start Report Guide
REFERENCES

1. Van Den Eeden et al. AUA 2017. Abstract 17-6551.
2. Klein et al. Eur Urol. 2014.
3. Cullen et al. Eur Urol. 2014.

*Adverse pathology defined as Gleason ≥4+3 and/or pT3+.
National Comprehensive Cancer Network (NCCN) and NCCN are registered trademarks of NCCN. NCCN does not endorse any product or therapy.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.